Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2015, Article ID 247892, 8 pages
http://dx.doi.org/10.1155/2015/247892
Research Article

Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer

1Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
2Centre for Cancer Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong

Received 9 March 2015; Revised 7 May 2015; Accepted 12 May 2015

Academic Editor: Yupo Ma

Copyright © 2015 Lui Ng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Shike, S. J. Winawer, P. H. Greenwald, A. Bloch, M. J. Hill, and S. V. Swaroop, “Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer,” Bulletin of the World Health Organization, vol. 68, no. 3, pp. 377–385, 1990. View at Google Scholar · View at Scopus
  2. T. Armaghany, J. D. Wilson, Q. Chu, and G. Mills, “Genetic alterations in colorectal cancer,” Gastrointestinal Cancer Research, vol. 5, no. 1, pp. 19–27, 2012. View at Google Scholar · View at Scopus
  3. J. J. Y. Sung, J. Y. W. Lau, G. P. Young et al., “Asia Pacific consensus recommendations for colorectal cancer screening,” Gut, vol. 57, no. 8, pp. 1166–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Lin, E. M. Webber, T. L. Beil, K. A. Goddard, and E. P. Whitlock, “Fecal DNA testing in screening for colorectal cancer in average-risk adults,” Tech. Rep. 12-EHC022-EF, Agency for Healthcare Research and Quality (US), Rockville, Md, USA, 2012. View at Google Scholar
  5. A. Bellahcène, V. Castronovo, K. U. E. Ogbureke, L. W. Fisher, and N. S. Fedarko, “Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer,” Nature Reviews Cancer, vol. 8, no. 3, pp. 212–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. E. Kruger, A. H. Miller, A. K. Godwin, and J. Wang, “Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers,” Critical Reviews in Oncology/Hematology, vol. 89, no. 2, pp. 330–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Likui, W. Hong, Z. Shuwen, Y. Yuangang, and W. Yan, “The potential of osteopontin as a therapeutic target for human colorectal cancer,” Journal of Gastrointestinal Surgery, vol. 15, no. 4, pp. 652–659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Ng, T. M. Wan, C. S. Lam et al., “Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer,” PLOS ONE, vol. 10, no. 5, Article ID e0126219, 2015. View at Publisher · View at Google Scholar
  9. M. Todaro, M. Gaggianesi, V. Catalano et al., “CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis,” Cell Stem Cell, vol. 14, no. 3, pp. 342–356, 2014. View at Publisher · View at Google Scholar
  10. V. Lamour, A. Henry, J. Kroonen et al., “Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo,” International Journal of Cancer, 2015. View at Publisher · View at Google Scholar
  11. L. Ng, R. Tung-Ping Poon, S. Yau et al., “Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion,” Hepatology, vol. 58, no. 2, pp. 667–679, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Luo, S. Li, B. Peng, Y. Ye, X. Deng, and K. Yao, “Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma,” PLoS ONE, vol. 8, no. 2, Article ID e56324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Gu, R. Ohashi, R. Cui et al., “Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer,” Lung Cancer, vol. 66, no. 2, pp. 176–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Graessmann, B. Berg, B. Fuchs, A. Klein, and A. Graessmann, “Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3,” Oncogene, vol. 26, no. 20, pp. 2840–2850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Qian, P. Li, W. Yan et al., “Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-kappaB/Bcl2 pathway,” Molecular Medicine Reports, vol. 11, no. 3, pp. 1951–1955, 2015. View at Google Scholar
  16. H. Kashihara, M. Shimada, N. Kurita et al., “CD133 expression is correlated with poor prognosis in colorectal cancer,” Hepatogastroenterology, vol. 61, no. 134, pp. 1563–1567, 2014. View at Google Scholar
  17. H. Hsu, Y. Liu, K. Tseng, B. C. Tan, S. Chen, and H. Chen, “LGR5 regulates survival through mitochondria-mediated apoptosis and by targeting the Wnt/β-catenin signaling pathway in colorectal cancer cells,” Cellular Signalling, vol. 26, no. 11, pp. 2333–2342, 2014. View at Publisher · View at Google Scholar
  18. E. Dotse and Y. Bian, “Isolation of colorectal cancer stem-like cells,” Cytotechnology, 2014. View at Publisher · View at Google Scholar
  19. Y.-X. Lu, L. Yuan, X.-L. Xue et al., “Regulation of colorectal carcinoma Stemness, Growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism,” Clinical Cancer Research, vol. 20, no. 10, pp. 2631–2642, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Han, X. Fang, X. Lou et al., “Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients,” PLoS ONE, vol. 7, no. 8, Article ID e41335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Yang, H. Wang, J. Zhang et al., “In vitro characterization of stem cell-like properties of drug-resistant colon cancer subline,” Oncology Research, vol. 21, no. 1, pp. 51–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Wen, Z. Fu, X. Wu, J. Feng, W. Chen, and J. Qian, “Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin,” Cancer Letters, vol. 333, no. 1, pp. 56–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. Tuck, A. F. Chambers, and A. L. Allan, “Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management,” Journal of Cellular Biochemistry, vol. 102, no. 4, pp. 859–868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Mi, S. D. Bhattacharya, V. M. Kim, H. Guo, L. J. Talbotq, and P. C. Kuo, “Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis,” Carcinogenesis, vol. 32, no. 4, pp. 477–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Bandopadhyay, A. Bulbule, R. Butti et al., “Osteopontin as a therapeutic target for cancer,” Expert Opinion on Therapeutic Targets, vol. 18, no. 8, pp. 883–895, 2014. View at Publisher · View at Google Scholar